Clene (NASDAQ: CLNN), together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extension (‘OLE’) of the RESCUE-ALS study as of July 2023, which showed a significant median survival benefit of 19.3 months in addition to a significant (p=0.049) 52% decreased risk of ALS clinical worsening events – defined as the first occurrence of death, tracheostomy (a procedure that involves creating an opening in the neck into the windpipe to help air and oxygen reach the lungs), assisted ventilation, or feeding tube placement – in patients originally treated with CNM-Au8. The data also showed a 75% decreased risk of long-term all-cause mortality,” reads a recent article. “A month later, the company reported long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the OLE of the HEALEY ALS platform trial. The post hoc results showed significantly improved survival compared to matched historical placebo controls from previously completed phase 2 and phase 3 ALS trials stored in the Pooled Resource Open-Access ALS Clinical Trials (‘PRO-ACT’) database, the largest U.S. clinical database of previous ALS trials.”
To view the full article, visit https://ibn.fm/kcHit
About Clene Inc.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
